STONEWALLCAPITAL | Contact Information

We use cookies for your convenience

Instruments

Economic Calendar What are CFDs Leverage Traders language Long - Buy order Short - Sell order CFD’s Advantage Assets
Account types
Education

Video Books News
Social Trading
About us

Who's Stonewall Capital Contact us Legal Documents Platform Partners

Client Area

Instruments

Economic Calendar What are CFDs Leverage Traders language Long - Buy order Short - Sell order CFD’s Advantage Assets
Account types
Education

Video Books News
Social Trading
About us

Who's Stonewall Capital Contact us Legal Documents Platform Partners
Client Area

Oppenheimer Reiterates ‘Outperform’ Rating on Abbott Laboratories (ABT)

Account types Platform Partners Legal documents

STONE WALL CAPITAL is a product of FINDEXA ADVISORY (PTY) LTD, an authorized Financial Services Provider, licensed and regulated by the Financial Sector Conduct Authority (FSCA) in South Africa with FSP No. 52500 and reg. No. 2022/504112/07, registered at 34 Shortens Country Estate Lee, Ballito, Kwa-Zulu Natal, 4420 South Africa, and its subsidiary FINDEXA ADVISOR EU LTD registered at Filosofou Lapithi, 40, 3117, Limassol, Cyprus. FINDEXA ADVISOR EU LTD acts as an EU billing agent to FINDEXA ADVISORY (PTY) LTD for transaction processing.

FINDEXA ADVISORY (PTY) LTD does not provide services to residents/citizens of certain jurisdictions, such as EU Member States, Iceland, Norway, Afghanistan, Canada, Iran, Iraq, Libya, Myanmar, Nicaragua, North Korea, Panama, Russian Federation, Somalia, Syria, Uganda, United Kingdom (UK), United States of America (USA), Yemen, Zimbabwe. For a full list of restricted countries contact our Support team.

RISK WARNING: Trading in financial instruments involves high risks including the risk of losing some or all of your investment amount, and may not be suitable for all investors. Prices of financial instruments can be extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instruments you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.